-- Their latest offerings are more than just tools. They're bridges. Built with scientists in mind who are navigating the early stages of therapeutic discovery, Creative Biolabs now offers a series of featured services that accelerate complementary therapeutic development.
The CH50 functional test kit is a hemolysis-based assay that quantifies the activity of the classical pathway of the complement system.
"This kit isn't just giving you data—it's giving you confidence," said a senior scientist with Creative Biolabs. "We've seen consistent, reproducible results in the lab, so it's a good early-stage screening tool."
For researchers designing complement-targeted drugs, such as small molecules or monoclonal antibodies, this kit provides a rapid and reproducible tool for assessing efficacy. This kit can also be used to screen or test the pharmaceutical activity of complement therapeutic inhibitors or activators. However, Creative Biolabs didn't stop there.
Their hemolysis inhibition profiling service takes the same principle and turns it into a comprehensive readout. Instead of measuring complement activation alone, it measures how well a drug can protect cells against lysis.
"It's not enough to know your drug binds to C5," explained a lead developer of assays. "You need to know whether that binding prevents the assembly of the membrane attack complex and spares cells from lysis. That's what our hemolysis assay reveals."
Creative Biolabs has also worked on the development of custom organ-on-chip and cell culture models. These microfluidic platforms replicate human organ architecture and behaviour, allowing researchers to replicate drug response in a dynamic, physiologically relevant setting.
"We've developed liver-kidney-on-a-chip systems that replicate metabolism and clearance in real time," one of the microfluidics researchers explained. "It's not cells in a petri dish anymore. It's mimicking the human body's complexity—minus the ethical and logistical woes of working with animals."
The organ-on-chip service is entirely customizable, with provisions for patient-derived cells, co-culture systems, and custom chip designs. It's an organic evolution of the company's ethos: that preclinical testing should be predictive, not merely a procedural step.
Validation of a complement inhibitor or modelling drug-drug interactions—Creative Biolabs has platforms that address both rigour and relevance. They are assisting scientists in creating smarter ones.
Learn more, please visit https://www.creative-biolabs.com/complement-therapeutics/.
About Creative Biolabs
Creative Biolabs facilitates preclinical investigations using advanced complement assays and organ-on-chip systems, thereby bridging molecular insights to propel drug discovery and therapeutic development.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Address: 17 Ramsey Road, Shirley, NY 11967, USA
Phone: 6318306441
Website: https://www.creative-biolabs.com/complement-therapeutics/
Release ID: 89173593
Google
RSS